The necessity for the discovery of innovative antimicrobials to treat life-threatening diseases
has increased as multidrug-resistant bacteria has spread. Due to antibiotics' availability over …

Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Tuberculosis (TB) is the most deadly infectious disease globally. Although most individuals
achieve a cure, a substantial portion develop multi-drug resistant TB which is exceedingly …

Tuberculosis (TB) is reported as one of the most prevailing life-threatening health problems,
affecting almost one third of the population globally. It is one of a major reason of death with …

Background: The design and development of prodrugs is the most common and effective
strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A …

ABSTRACT A milestone in the development of novel antituberculosis drugs is the
demonstration of early bactericidal activity (EBA) in a phase IIa clinical trial. The significant …

Introduction Tuberculosis requires lengthy multi-drug therapy. Mycobacterium tuberculosis
occupies different tissue compartments during infection, making drug access and …

ABSTRACT A population pharmacokinetic (PopPK) model for pretomanid was developed
using data from 14 studies in the pretomanid development program: six phase 1 studies, six …

Shorter, more potent regimens are needed for tuberculosis. The nitroimidazole pretomanid
was recently approved for extensively drug-resistant tuberculosis in combination with …

Bedaquiline is a diarylquinoline antimycobacterial drug and a key component of several
regimens in clinical development for the treatment of tuberculosis (TB) but with ongoing …